The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2021 | Monoclonal antibodies for smoldering or newly diagnosed myeloma
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, discusses the role of monoclonal antibody therapies in the treatment of patients with smoldering or newly diagnosed multiple myeloma. In particular, Dr Zamagni discusses the use of monoclonal antibodies in the first-line setting in combination with immunomodulatory drugs and proteasome inhibitors. Dr Zamagni also highlights the potential of monoclonal antibodies to delay disease progression in patients with smoldering multiple myeloma. This interview took place during the 2021 European Myeloma Network (EMN) congress.
Disclosures
Elena Zamagni, MD, PhD, has received honoraria from, and participated in advisory boards for Amgen, Sanofi, BMS, Takeda, Janssen, Oncopeptides and Karyopharm.
